Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000549870 | SCV000629450 | pathogenic | Spastic paraplegia | 2020-06-21 | criteria provided, single submitter | clinical testing | This sequence change results in a premature translational stop signal in the SACS gene (p.Glu3647*). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 933 amino acids of the SACS protein. For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the SACS protein. Other variant(s) that disrupt this region (p.Arg3903*) have been determined to be pathogenic (PMID: 19892370, 21745802). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has not been reported in the literature in individuals with SACS-related conditions. This variant is not present in population databases (ExAC no frequency). |
Athena Diagnostics | RCV003482277 | SCV004229936 | likely pathogenic | not provided | 2023-05-16 | criteria provided, single submitter | clinical testing | This variant is expected to result in the loss of a functional protein. The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). |
Baylor Genetics | RCV004568750 | SCV005055521 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2024-03-04 | criteria provided, single submitter | clinical testing |